Equities analysts expect that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will report sales of $161.76 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Halozyme Therapeutics’ earnings, with the highest sales estimate coming in at $187.15 million and the lowest estimate coming in at $147.57 million. Halozyme Therapeutics posted sales of $39.00 million during the same quarter last year, which suggests a positive year over year growth rate of 314.8%. The business is scheduled to announce its next quarterly earnings report after the market closes on Tuesday, February 20th.
On average, analysts expect that Halozyme Therapeutics will report full year sales of $161.76 million for the current fiscal year, with estimates ranging from $314.20 million to $314.30 million. For the next financial year, analysts expect that the firm will post sales of $138.73 million per share, with estimates ranging from $123.20 million to $154.26 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow Halozyme Therapeutics.
A number of research firms have commented on HALO. Zacks Investment Research lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 25th. Deutsche Bank set a $21.00 price objective on Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Goldman Sachs Group began coverage on Halozyme Therapeutics in a research note on Wednesday, January 24th. They set a “neutral” rating and a $20.00 price objective on the stock. BidaskClub lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, Barclays lowered Halozyme Therapeutics from an “overweight” rating to a “hold” rating and raised their price objective for the stock from $16.00 to $19.00 in a research note on Wednesday, November 22nd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company’s stock. Halozyme Therapeutics has an average rating of “Hold” and an average price target of $19.25.
Halozyme Therapeutics (HALO) opened at $18.48 on Wednesday. Halozyme Therapeutics has a 52 week low of $11.41 and a 52 week high of $21.13. The company has a debt-to-equity ratio of 2.01, a quick ratio of 3.37 and a current ratio of 3.46. The company has a market capitalization of $2,630.00, a price-to-earnings ratio of -27.18 and a beta of 1.98.
ILLEGAL ACTIVITY NOTICE: “Halozyme Therapeutics, Inc. (HALO) Expected to Post Quarterly Sales of $161.76 Million” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.com-unik.info/2018/02/21/halozyme-therapeutics-inc-halo-expected-to-post-quarterly-sales-of-161-76-million.html.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.